Background and Objectives: Since publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID-19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study provides an in-depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/ STEMI, intracranial hemorrhage, thrombosis (deep vein thrombosis, cerebral venous thrombosis, arterial or venous thrombotic events, portal vein thrombosis, coronary thrombosis, microvascular small bowel thrombosis), and pulmonary embolism. Methods: A systematic review of original studies reporting confirmed cardiovascular manifestations post-mRNA COVID-19 vaccination was performed. Following the PRISMA guidelines, electronic databases (PubMed, PMC NCBI, and Cochrane Library) were searched until January 2022. Baseline characteristics of patients and disease outcomes were extracted from relevant studies. Results: A total of 81 articles analyzed confirmed cardiovascular complications post-COVID-19 mRNA vaccines in 17,636 individuals and reported 284 deaths with any mRNA vaccine. Of 17,636 cardiovascular events with any mRNA vaccine, 17,192 were observed with the BNT162b2 (Pfizer−BioNTech)vaccine, 444 events with mRNA-1273 (Moderna). Thrombosis was frequently reported with any mRNA vaccine (n = 13,936), followed by stroke (n = 758),

No abstract

Yellow nail syndrome is a very rare disorder that has been noticed since 1927. 1 It affects both sexes equally, with an age of more than 40 years being typical. 2 The exact pathogenesis remains unclear but lymphatic system anatomical and functional abnormalities remain the predominant theory, while other hypotheses suggest autoimmune, cancer, and paraneoplastic roles. 3 Also, a very rare familial case has been reported. 1 Although it is only found in 27%-60% of patients The diagnosis depends on the presence of 2 out; of the characteristic nail changes, respiratory tract infection, and lymphedema. The latter occurs in up to 80% of cases and

Background: The menstrual cycle in women is the main indicator of their reproductive health which is affected by the ongoing coronavirus disease 2019 pandemic. This review aims to summarize the effects of the COVID-19 infection and the global pandemic on the menstrual health of women. Methods:The literature search was conducted in PubMed, Cochrane library, and Google Scholar using keywords "COVID-19," "Menstrual Cycle," "Menstrual Cycle Irregularities," "Amenorrhea," "Polymenorrhea," and "Dysmenorrhea." The articles were selected according to the following inclusion criteria: (i) cross-sectional studies, (ii) cohort studies, (iii) surveys, and (iv) other observational studies observing the effects of SARS-CoV-2 infection or COVID-19 pandemic on menstrual health of women. Exclusion criteria included: case reports, gray literature, and website articles regarding menstrual health.Results: A total of 30,510 articles were shortlisted after a comprehensive search.Sixteen articles were included out of which 13 studies investigated the effects of the COVID-19 pandemic on the menstrual cycle while 3 evaluated the possible effects of COVID-19 infection on the menstrual health of women. Menstrual disorders or irregularities were a more common finding during the pandemic as compared to before (p = 0.008). Women affected by pandemic-related stress were more prone to changes in the duration of their menses (p = 0.0008), reported heavier bleeding (p = 0.028), and increased incidence of painful periods (p < 0.0001). COVID-19 infected women also reported changes in their menstrual cycle including irregular menstruation, increased symptoms of premenstrual syndrome, and infrequent menstruation.Conclusions: Women suffering from COVID-19 infection or pandemic-associated stress and anxiety were more likely to experience irregular menstruation, dysmenorrhea,

Background Since December 2019, (COVID‐19) has had a significant impact on global health systems. Because little is known about the clinical characteristics and risk factors connected with COVID‐19 severity in Sudanese patients, it is vital to summarize the clinical characteristics of COVID‐19 patients and to investigate the risk factors linked to COVID‐19 severity. Objectives We aimed to assess the clinical characteristics of COVID‐19 patients and look into risk factors associated with COVID‐19 severity. Methods This is a retrospective cross‐sectional study that took place in two Isolation Centers in Wad Medani, Gezira State, Sudan. Four hundred and eighteen patients were included between May 2020 and May 2021. All COVID‐19 patients over the age of 18 who were proven COVID‐19 positive by nucleic acid testing or had characteristics suggestive of COVID‐19 on a chest CT scan and had a complete medical record in the study period were included. Results The participants in this study were 418 confirmed COVID‐19 cases with a median age of 66.313 years. There were 279 men (66.7%) among the patients. The most prevalent comorbidities were hypertension (n = 195; 46.7%) and diabetes (n = 187; 44.7%). Fever (n = 303; 72.5%), cough (n = 278; 66.5%), and dyspnea (n = 256; 61.2%) were the most prevalent symptoms at the onset of COVID‐19. The overall mortality rate (n = 148) was 35.4%. Patients with severe illness had a mortality rate of 42.3% (n = 118). Older age, anemia, neutrophilia, and lymphocytopenia, as well as higher glucose, HbA1c, and creatinine levels, were all linked to severe COVID‐19, according to the chi‐square test and analysis of variance analysis. Conclusion Sixteen variables were found to be associated with COVID‐19 severity. These patients are more prone to go through a serious infection and as a result have a greater death rate than those who do not have these characteristics.

Malaria and coronavirus disease 2019 (COVID‐19) share several characteristics that could lead to cross‐infection, particularly in malaria‐endemic areas. Early COVID‐19 symptoms might be misdiagnosed for malaria in clinical settings. Also, both diseases can cause fatal complications. So, laboratory testing for both diseases was recommended by the World Health Organization. To study the clinical characteristics and outcomes of Adult Sudanese patients with COVID‐19 and malaria coinfection. This retrospective cross‐sectional study was conducted from January 2021 to October 2021 in Wad Medani. Total coverage of all Sudanese patients above 18 years old with a confirmed diagnosis of coinfection with COVID‐19 and malaria was included, and data were collected using a data collection sheet. Data were analyzed using R software version 4.0.2. Data were described and presented as mean, standard deviation, and number (percentage). To find associated factors with in‐hospital outcome, χ 2 test, fisher exact test, and independent t test or Wilcoxon rank‐sum test were used. In this study, 156 participants were diagnosed with COVID‐19 and malaria coinfection. Most of them were between 60 and 70 years (30.8%), the majority were males (59%). Shortness of breath (76.3%) and acute respiratory distress syndrome (35.3%) were the most common symptom and complications among coinfected patients, respectively. Ground glass opacity ( n = 47/49, 95.9%) is the most common result for computed tomography scan. Atrial fibrillation was the most common abnormal electrocardiogram finding ( n = 6/62, 9.7%). Overall mortality among all participants was (63/156, 40.4%). High mortality rate was found among the coinfected patients. More attention is needed towards fighting COVID‐19 and malaria coinfection. There may be a link between malaria and COVID‐19.

Background Coronavirus disease 2019 (COVID‐19) vaccine side effects have an important role in the hesitancy of the general population toward vaccine administration. Therefore, this study was conducted to document the COVID‐19 vaccine side effects in our population. Materials and Methods An online survey‐based, cross‐sectional study was carried out from September 1, 2021, to October 1, 2021, to document the side effects of the COVID‐19 vaccine among the general public. The questionnaire included participants’ sociodemographic data, type of vaccine, comorbidities, previous COVID‐19 infection, and assessment of side effects reported by them. Results The majority of the participants were <20 years of age (62.2%), females (74.9%), belonged to the educational sector (58.1%), residents of Sindh (65.7%), and were previously unaffected by COVID‐19 infection (73.3%). Sinovac (38.7%) followed by Sinopharm (30.4%) and Moderna (18.4%) were administered more frequently. Commonly reported side effects were injection site pain (82%), myalgia (55%), headache (46%), fatigue/malaise (45%), and fever (41%). Vaccine side effects were more likely to be reported with the first dose as compared to the second dose. On regression analysis, factors associated with occurrence of side effects included younger age (odds ratio [OR]: 6.000 [2.065–17.431], p < 0.001), female gender (OR: 2.373 [1.146–4.914], p = 0.020), marital status (OR: 0.217 [0.085–0.556], p < 0.001), graduate level of education (OR: 0.353 [0.153–0.816], p = 0.015), and occupation being either retired, freelancers, or social workers (OR: 0.310 [0.106–0.909]), p = 0.033). Previous infection with COVID‐19 ( p = 0.458) and comorbidities were found unrelated ( p = 0.707) to the occurrence of side effects. Conclusion The overall prevalence of local side effects was quite higher than the systemic ones. Further large‐scale studies on vaccine safety are required to strengthen public confidence in the vaccination drive.

Background Monkeypox is a zoonotic disease caused by Monkeypox virus, an Orthopoxvirus. The 2022 Monkeypox outbreak has provoked a considerable amount of fear among the public. Awareness about this disease would modify the public attitudes in the fight against Monkeypox. We conducted this study aiming to assess the awareness and prediction of the middle east public about Monkeypox. Methods This cross-sectional study was conducted in August 2022. Data were collected from eight middle east countries using an online self-administered questionnaire distributed through educational and social media platforms. Statistical analysis was conducted using SPSS version 26. Results About 11,016 individuals have participated in this study. The majority of the participants have not seen a Monkeypox case, but will not travel to a country with the epidemic. Most of the participants knew the causative organism. Importantly, the majority were not aware of Monkeypox mode of transmission, symptoms, complications, and vaccination. A considerable proportion were aware of the disease protective measures. Participants' awareness was mostly gained from social media and it varied by age, gender, educational level, and country. The majority predicted acquiring Monkeypox when protective measures not taken, progression to a pandemic with economic consequences, and ability of ministry of health to control the epidemic. Participants' predictions varied by their country. Conclusion Middle east public knowledge about monkeypox is poor. Raising awareness about Monkeypox (especially mode of transmission, symptoms, and preventive measures) would be of benefit in controlling the epidemic. This study constitutes an evidence upon which health education programs could be designed.